News Conference News ACC 2017 SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients Todd Neale March 17, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017